AstraZeneca CTLA-4 Inhibitor Imjudo (Finally) Wins FDA Approval
Pharma To Carve HCC Niche On Survival Data
More than a decade after Pfizer gave up on it, tremelimumab won approval combined with PD-L1 inhibitor Imfinzi for frontline hepatocellular carcinoma, ahead of Bristol’s Yervoy/Opdivo second-line indication.
